SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma

索拉非尼 医学 肝细胞癌 选择性内照射治疗 内科学 危险系数 不利影响 临床终点 人口 门静脉血栓形成 放射治疗 胃肠病学 肿瘤科 外科 随机对照试验 置信区间 血栓形成 环境卫生
作者
Pierce K. H. Chow,Mihir Gandhi,Say Beng Tan,Maung Win Khin,Ariunaa Khasbazar,Janus Ong,Su Pin Choo,Peng Chung Cheow,Chanisa Chotipanich,Kieron Lim,Laurentius Adrianto Lesmana,Tjakra Wibawa Manuaba,Boon Koon Yoong,Aloysius Raj,Chiong Soon Law,Ian H.Y.,Rolley Rey Lobo,Catherine S. C. Teh,Yun Hwan Kim,Yun Won Jong
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:36 (19): 1913-1921 被引量:703
标识
DOI:10.1200/jco.2017.76.0892
摘要

Purpose Selective internal radiation therapy or radioembolization (RE) shows efficacy in unresectable hepatocellular carcinoma (HCC) limited to the liver. This study compared the safety and efficacy of RE and sorafenib in patients with locally advanced HCC. Patients and Methods SIRveNIB (selective internal radiation therapy v sorafenib), an open-label, investigator-initiated, phase III trial, compared yttrium-90 ( 90 Y) resin microspheres RE with sorafenib 800 mg/d in patients with locally advanced HCC in a two-tailed study designed for superiority/detriment. Patients were randomly assigned 1:1 and stratified by center and presence of portal vein thrombosis. Primary end point was overall survival (OS). Efficacy analyses were performed in the intention-to-treat population and safety analyses in the treated population. Results A total of 360 patients were randomly assigned (RE, 182; sorafenib, 178) from 11 countries in the Asia-Pacific region. In the RE and sorafenib groups, 28.6% and 9.0%, respectively, failed to receive assigned therapy without significant cross-over to either group. Median OS was 8.8 and 10.0 months with RE and sorafenib, respectively (hazard ratio, 1.1; 95% CI, 0.9 to 1.4; P = .36). A total of 1,468 treatment-emergent adverse events (AEs) were reported (RE, 437; sorafenib, 1,031). Significantly fewer patients in the RE than sorafenib group had grade ≥ 3 AEs (36 of 130 [27.7%]) v 82 of 162 [50.6%]; P < .001). The most common grade ≥ 3 AEs were ascites (five of 130 [3.8%] v four of 162 [2.5%] patients), abdominal pain (three [2.3%] v two [1.2%] patients), anemia (zero v four [2.5%] patients), and radiation hepatitis (two [1.5%] v zero [0%] patients). Fewer patients in the RE group (27 of 130 [20.8%]) than in the sorafenib group (57 of 162 [35.2%]) had serious AEs. Conclusion In patients with locally advanced HCC, OS did not differ significantly between RE and sorafenib. The improved toxicity profile of RE may inform treatment choice in selected patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Ma发布了新的文献求助10
刚刚
1秒前
lin发布了新的文献求助10
2秒前
MRCHONG发布了新的文献求助10
2秒前
3秒前
3秒前
3秒前
往海深处听完成签到,获得积分10
3秒前
yangyu发布了新的文献求助20
3秒前
4秒前
5秒前
小豆包发布了新的文献求助10
5秒前
Ava的应助被不以物喜采纳,获得10
5秒前
杨瑞关注了科研通微信公众号
5秒前
5秒前
wanci的应助被简单灵凡采纳,获得10
5秒前
5秒前
6秒前
研友_VZG7GZ的应助被弦弦弦采纳,获得10
6秒前
不知完成签到,获得积分10
7秒前
立菠萝发布了新的文献求助10
8秒前
任风发布了新的文献求助10
8秒前
Wxh完成签到,获得积分10
8秒前
8秒前
9秒前
小马甲的应助被晚上好采纳,获得10
9秒前
科研通AI6.2的应助被Nowaki采纳,获得10
9秒前
huakeguanli发布了新的文献求助10
9秒前
雪山大地发布了新的文献求助10
11秒前
11秒前
倾尽的应助被Ma采纳,获得10
12秒前
小马甲的应助被李奥采纳,获得10
13秒前
13秒前
咩咩努力写论文完成签到,获得积分10
13秒前
晚上好完成签到 ,获得积分10
13秒前
14秒前
lynn完成签到 ,获得积分10
14秒前
zxp的应助被刘kk采纳,获得10
14秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163835
求助须知:如何正确求助?哪些是违规求助? 9557925
关于积分的说明 21742693
捐赠科研通 7754454
什么是DOI,文献DOI怎么找? 3428350
关于科研通互助平台的介绍 2553034
邀请新用户注册赠送积分活动 2472982